Jaffer A. Ajani
YOU?
Author Swipe
View article: Efficacy and Safety of Anti–PD-(L)1 Treatments: A Systematic Review and Meta-Analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anti–PD-(L)1 Treatments: A Systematic Review and Meta-Analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma Open
View article: Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis Open
Background Several programmed cell death protein-1 inhibitors are approved for the first-line treatment of advanced gastric/gastroesophageal junction cancer, including pembrolizumab, nivolumab and, more recently, tislelizumab. Since direct…
View article: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B Open
Biomarker-enriched, chemotherapy-free treatments for patients with advanced gastric and gastroesophageal junction cancer have not been widely explored. In this multicenter, phase 2 trial (NCT04363801), we evaluated the efficacy and safety …
View article: 454P Global physician and patient-reported symptom concordance in association with quality of life in HER2-negative advanced gastric, gastroesophageal or esophageal adenocarcinoma
454P Global physician and patient-reported symptom concordance in association with quality of life in HER2-negative advanced gastric, gastroesophageal or esophageal adenocarcinoma Open
View article: 417P Comparative efficacy and safety of tislelizumab (TIS) vs other anti–PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): A network meta-analysis (NMA)
417P Comparative efficacy and safety of tislelizumab (TIS) vs other anti–PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): A network meta-analysis (NMA) Open
View article: Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers
Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers Open
Background Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, has demonstrated efficacy and safety in solid tumors. This analysis evaluates its long-term safety. Patients and Methods A retrospective analysis was per…
View article: Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma
Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma Open
PURPOSE To compare overall survival (OS) in patients with baseline metastatic gastric adenocarcinoma (GA) with and without ovarian metastasis (OM). Furthermore, within the group that had ovarian metastases, we aimed to assess whether there…
View article: Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial Open
There is a need for novel therapies for patients with previously treated HER2-positive gastroesophageal adenocarcinoma (GEA). This phase 1 (NCT02892123) dose-escalation and expansion trial evaluated zanidatamab (a dual HER2-targeted bispec…
View article: KAP1 promotes gastric adenocarcinoma progression by activating Hippo/YAP1 signaling via binding to HNRNPAB
KAP1 promotes gastric adenocarcinoma progression by activating Hippo/YAP1 signaling via binding to HNRNPAB Open
View article: Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells
Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells Open
All lesions in the evolution of EAC possess discrete populations of stem cells that are potential therapeutic targets.
View article: Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial Open
View article: Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study
Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study Open
Background: This study aims to develop consensus-based guidelines to prevent and manage nausea and vomiting in patients treated with zolbetuximab plus chemotherapy. Materials and methods: An international Delphi panel included 15 experts w…
View article: Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?
Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma? Open
Whether preoperative chemoradiotherapy (CRT) or perioperative chemotherapy is superior for localized esophageal or gastro-esophageal junction (GEJ) cancers has been a topic of long-standing debate. For years, standard of care in the United…
View article: Exosomal Galectin-3 promotes peritoneal metastases in gastric adenocarcinoma via microenvironment alterations
Exosomal Galectin-3 promotes peritoneal metastases in gastric adenocarcinoma via microenvironment alterations Open
View article: Changing landscapes and increasing relevance of immunotherapy in localized MSI-H gastric adenocarcinoma
Changing landscapes and increasing relevance of immunotherapy in localized MSI-H gastric adenocarcinoma Open
View article: Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data
Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data Open
Correlations between DFS and OS were meaningful at both individual and treatment effect level. The derived surrogacy equation enables reliable early assessments of OS benefit from the observed DFS benefit for early-stage EC/GEJC treatments…
View article: DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish Open
PURPOSE The outcomes of anti–PD-1 agents plus fluoropyrimidine/platinum in frontline advanced gastroesophageal adenocarcinomas (aGEAs) remain poor. We investigated the safety, tolerability, and activity of fluoropyrimidine/oxaliplatin and …
View article: Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing Open
Characteristics of individual discordant HER2 cases
View article: Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing Open
Characteristics of individual discordant HER2 cases
View article: Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers Open
Supplemental Figures 1 - 5
View article: Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers Open
Supplemental Figures 1 - 5
View article: Data from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Data from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers Open
Purpose: Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy. Experimental Design: Copy number and genomic sequencing data …
View article: Data from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Data from Discordance of HER2 Expression and/or Amplification on Repeat Testing Open
We sought to assess discordance of HER2 status in patients with HER2 amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with metastatic solid tumors and HER2 expression by immunohistochemistry (IHC) or am…
View article: Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing Open
Distribution of HER2 IHC and FISH results between local and central testing.
View article: Table S1, Table S2, Table S3 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Table S1, Table S2, Table S3 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers Open
Supplemental Tables 1 - 3
View article: Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing Open
Distribution of HER2 IHC and FISH results between local and central testing.
View article: Table S1, Table S2, Table S3 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Table S1, Table S2, Table S3 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers Open
Supplemental Tables 1 - 3
View article: Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma Open
View article: METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics Open
Recent advances in spatial transcriptomics (ST) techniques provide valuable insights into cellular interactions within the tumor microenvironment (TME). However, most analytical tools lack consideration of histological features and rely on…
View article: Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials Open
Patients in SPOTLIGHT and GLOW maintained measured HRQoL relative to baseline when treated with first-line zolbetuximab added to chemotherapy. Zolbetuximab plus chemotherapy improved PFS and OS without negatively affecting HRQoL in key PRO…